Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 2

Sponsor

Conditions

Multiple Sclerosis 2Carcinoma in Situ 2Multiple Sclerosis, Relapsing-Remitting 1Multiple Sclerosis, Chronic Progressive 1

Interventions

valrubicin 3dodecyl maltoside 3Mitomycin 2Interferon beta-1b 2Gemcitabine 2pembrolizumab 1enfortumab vedotin 1cemiplimab 1apaziquone 1Standard of Care 1Oncolytic Virotherapy 1Interferons 1Imiquimod 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1BCG Vaccine 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma in Situ × Interferon beta-1b × Clear all
NCT02486640 2023-07-24

BETAPREDICT

Bayer

Completed
162 enrolled

Carcinoma in Situ, Multiple Sclerosis

NCT03134573 2019-03-26

PROmyBETAapp

Bayer

Completed
96 enrolled

Carcinoma in Situ, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡